Low vs. Moderate to High Dose Vitamin D for Prevention of COVID-19
et al., NCT04868903, NCT04868903, Dec 2024
Vitamin D for COVID-19
8th treatment shown to reduce risk in
October 2020, now with p < 0.00000000001 from 136 studies, recognized in 18 countries.
No treatment is 100% effective. Protocols
combine treatments.
6,300+ studies for
210+ treatments. c19early.org
|
RCT 923 outpatients with baseline vitamin D levels 36 ng/ml, comparing 400, 4,000, and 10,000 IU vitamin D per day, showing lower cases with 4,000 IU vs. 400 IU, significant in Cox multivariable analysis. There was no benefit seen for 10,000 IU. There was no control group, and there was no hospitalization or more severe outcomes in any group.
This is the 41st COVID-19 RCT for vitamin D, which collectively show efficacy with p=0.0000001.
This is the 137th COVID-19 controlled study for vitamin D, which collectively show efficacy with p<0.0000000001 (1 in 12 octillion).
Standard of Care (SOC) for COVID-19 in the study country,
the USA, is very poor with very low average efficacy for approved treatments1.
Only expensive, high-profit treatments were approved for early treatment. Low-cost treatments were excluded, reducing the probability of early treatment due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments.
|
risk of case, 1.0% lower, HR 0.99, p = 0.98, treatment 162, control 162, adjusted per study, 10,000 IU vs. 400 IU, multivariable, Cox proportional hazards.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Meltzer et al., 10 Dec 2024, Double Blind Randomized Controlled Trial, USA, preprint, 1 author, dosage 10,000IU daily, trial NCT04868903 (history).
Contact: dmeltzer@bsd.uchicago.edu.
